Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-2990 in Japanese cedar pollen-induced seasonal allergic rhinitis
NCT03570957Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT-2990 in seasonal allergic rhinitis (SAR) (5 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoints: Adverse Events at 113 days and Anti-Drug Antibodies at 113 days. Started Jul 2018; status: completed.
02
Drugs
MT-2990
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT03570957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570957.